Skye Historical Financial Ratios
| SKYE Stock | USD 4.41 0.13 3.04% |
Skye Bioscience, is promptly reporting on over 84 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Average Payables of 1.4 M, Stock Based Compensation To Revenue of 0.0, Capex To Depreciation of 0.096 or Ev To Sales of 275 will help investors to properly organize and evaluate Skye Bioscience, Common financial condition quickly.
Skye |
About Skye Financial Ratios Analysis
Skye Bioscience, CommonFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Skye Bioscience, investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Skye financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Skye Bioscience, history.
Skye Bioscience, Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Skye Bioscience, Common stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Skye Bioscience, sales, a figure that is much harder to manipulate than other Skye Bioscience, Common multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Most ratios from Skye Bioscience,'s fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Skye Bioscience, Common current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. At present, Skye Bioscience,'s Income Quality is projected to slightly decrease based on the last few years of reporting. The current year's ROE is expected to grow to 18.54, whereas Book Value Per Share is forecasted to decline to (0.32).
| 2023 | 2024 (projected) | Graham Number | 6.07 | 5.76 | Receivables Turnover | 12.07 | 12.68 |
Skye Bioscience, fundamentals Correlations
Click cells to compare fundamentals
Skye Bioscience, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Skye Bioscience, fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 31.79 | 22.78 | 3.61 | (2.64) | (8.94) | (8.49) | |
| Book Value Per Share | 1.03 | 0.44 | 3.61 | (1.52) | (0.3) | (0.32) | |
| Free Cash Flow Yield | (0.0751) | (0.35) | (0.59) | (1.61) | (0.73) | (0.77) | |
| Operating Cash Flow Per Share | (11.33) | (5.89) | (3.98) | (6.42) | (1.99) | (2.09) | |
| Pb Ratio | 31.79 | 22.78 | 3.61 | (2.64) | (8.94) | (8.49) | |
| Free Cash Flow Per Share | (11.33) | (5.9) | (4.04) | (6.44) | (1.99) | (2.09) | |
| Roic | (7.08) | (3.23) | (1.0) | 16.59 | (6.1) | (5.8) | |
| Net Income Per Share | 1.98 | (6.39) | (5.24) | (9.82) | (5.37) | (5.64) | |
| Payables Turnover | 0.0105 | 0.004909 | 0.0379 | 0.0641 | 0.11 | 0.1 | |
| Cash Per Share | 3.44 | 2.4 | 5.52 | 0.63 | 0.18 | 0.17 | |
| Pocfratio | (2.89) | (1.7) | (3.27) | (0.62) | (1.37) | (1.3) | |
| Interest Coverage | (6.71) | (8.9) | (10.22) | (27.53) | (15.09) | (15.84) | |
| Pfcf Ratio | (2.89) | (1.69) | (3.22) | (0.62) | (1.36) | (1.3) | |
| Days Payables Outstanding | 34.9K | 74.4K | 9.6K | 5.7K | 3.4K | 3.2K | |
| Income Quality | (5.73) | 0.92 | 0.76 | 0.65 | 0.37 | 0.39 | |
| Roe | 1.92 | (14.55) | (1.45) | 6.48 | 17.66 | 18.54 | |
| Ev To Operating Cash Flow | (2.65) | (1.54) | (2.21) | (0.68) | (1.61) | (1.53) | |
| Pe Ratio | 16.56 | (1.57) | (2.48) | (0.41) | (0.51) | (0.48) | |
| Return On Tangible Assets | 0.53 | (2.46) | (0.86) | (2.14) | (3.15) | (3.31) | |
| Ev To Free Cash Flow | (2.65) | (1.53) | (2.18) | (0.67) | (1.61) | (1.52) | |
| Earnings Yield | 0.0604 | (0.64) | (0.4) | (2.46) | (1.98) | (1.88) | |
| Net Debt To E B I T D A | (0.71) | 0.15 | 0.88 | (0.0564) | (0.25) | (0.26) | |
| Current Ratio | 2.05 | 3.38 | 2.46 | 0.74 | 0.84 | 0.8 | |
| Tangible Book Value Per Share | 1.03 | 0.44 | 3.61 | (1.52) | (0.3) | (0.32) | |
| Graham Number | 6.77 | 7.94 | 20.62 | 18.31 | 6.07 | 5.76 | |
| Shareholders Equity Per Share | 1.03 | 0.44 | 3.61 | (1.52) | (0.3) | (0.32) | |
| Debt To Equity | 0.71 | 3.32 | 0.34 | (0.63) | (2.05) | (1.95) | |
| Graham Net Net | 0.72 | 0.24 | 3.07 | (3.64) | (1.87) | (1.96) | |
| Interest Debt Per Share | 2.58 | 2.15 | 1.69 | 1.3 | 0.75 | 0.72 | |
| Debt To Assets | 0.7 | 0.19 | 0.56 | 0.2 | 0.21 | 0.37 | |
| Enterprise Value Over E B I T D A | 7.82 | (1.48) | (1.83) | (0.71) | (1.65) | (1.57) | |
| Price Earnings Ratio | 16.56 | (1.57) | (2.48) | (0.41) | (0.51) | (0.48) | |
| Price Book Value Ratio | 31.79 | 22.78 | 3.61 | (2.64) | (8.94) | (8.49) | |
| Price Earnings To Growth Ratio | (0.16) | 0.003703 | 0.14 | (0.00466) | 0.0112 | 0.0117 | |
| Days Of Payables Outstanding | 34.9K | 74.4K | 9.6K | 5.7K | 3.4K | 3.2K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.